Witryna13 sie 2024 · 当地时间8月11日,美国生物制药公司Mersana Therapeutics 宣布其抗体偶联药物(ADCs)XMT-1536获得美国FDA授予的快速通道资格,用于治疗铂类耐药性 … Witryna22 cze 2024 · Preclinical data on multiple Immunosynthen STING-agonist ADCs show complete tumor regressions after a single dose, excellent tolerability and immune memory ; CAMBRIDGE, Mass., June 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc.. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company …
患者死亡,Mersana的HER2 ADC暂停临床 - 网易
Witryna7 paź 2024 · The Company has evaluated Immunosynthen ADCs across a wide range of antibodies, targets, tumor models and mouse strains and observed broad efficacy and consistent results demonstrating target-dependent anti-tumor effects and has selected HER2 as the first target for clinical evaluation with XMT-2056. The Company … WitrynaMersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. ... XMT-1660, in Investigational New Drug (IND)-enabling studies; and has nominated its first Immunosynthen development ... electric fan controller sensor oreillys
Mersana Therapeutics Provides Business Update and Announces …
Witryna16 lip 2024 · Compared with CD11b-targeted ADCs, cell–targeted ADCs resulted in a greater production of interferons and other cytokines and stronger cancer cell killing. … Witryna8 paź 2024 · XMT-2056 is an Immunosynthen STING-agonist ADC candidate, targeting an epitope of human epidermal growth factor receptor 2 (HER2). ... Immunosynthen … Witryna31 gru 2024 · Entered Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany: In December 2024, Mersana announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to … foods that increase ed